Humacyte's MAA Application Accepted by Israel Ministry of Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy HUMA?
Humacyte announced that its Marketing Authorization Application, MAA, seeking approval of the acellular tissue engineered vessel for arterial trauma repair has been accepted by the Israel Ministry of Health. The Ministry of Health has set a 180-working-day review period for the MAA due to the existing Food and Drug Administration, FDA, approval of Symvess in extremity vascular trauma. "We are very pleased that the Ministry of Health has accepted our MAA filing and has granted a 180-day review period," said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. "The MAA acceptance us another step in our planned global expansion of Symvess as we seek to provide this innovative regenerative medicine product to patients throughout the world. Many patients with severe vascular injuries are underserved by the current standard of care, and we are proud of the results that have been seen in our clinical trials and real-world humanitarian efforts.".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.688
Low
3.00
Averages
5.88
High
11.00
Current: 0.688
Low
3.00
Averages
5.88
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh LLC Investigates Humacyte Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages Humacyte shareholders to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests and seek legal remedies.
- Corporate Governance Reform: The investigation aims to determine whether Humacyte executives breached their fiduciary duties to shareholders, and if so, shareholders may seek governance reforms and fund recovery, thereby enhancing the company's transparency and accountability.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, which reduces the financial burden of participating in legal action and encourages more shareholders to engage.
- Investor Rights Advocacy: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
HUMACYTE INC.: BARCLAYS LOWERS TARGET PRICE FROM $3.5 TO $1.5
- Barclays Target Price Cut: Barclays has reduced its target price for Humacyte from $3.50 to $1.50.
- Market Impact: This significant cut reflects a shift in market expectations regarding Humacyte's performance and potential.
See More
Humacyte Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: In Q4 2025, Humacyte reported revenues of $0.5 million, with $0.4 million from U.S. sales of Symvess and $0.1 million from research collaborations, although the net loss widened to $24.8 million, indicating potential for sales growth despite challenges.
- Improved Net Loss: The full-year net loss for 2025 narrowed significantly to $40.8 million from $148.7 million in 2024, primarily due to non-cash gains related to liability remeasurements, reflecting an improvement in the company's financial health.
- Product Commercialization Progress: By the end of 2025, 27 hospitals had ordered Symvess, which was FDA-approved in December 2024, with multiple re-orders indicating growing market demand, while a $1.475 million commitment from Saudi Arabia for clinical evaluation further supports international expansion.
- R&D Pipeline Developments: Interim Phase 3 results for ATEV are expected in Q2 2026, and positive data could support a BLA filing in the second half of the year, while an IND for CTEV has been submitted, with a first-in-human Phase 1 trial planned for H2 2026, showcasing the company's ongoing innovation in bioengineered vessels.
See More
Humacyte Q4 Earnings Report Analysis
- Earnings Performance: Humacyte reported a Q4 GAAP EPS of -$0.13, aligning with expectations, but its revenue of $0.47 million fell short by $0.88 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, Humacyte had cash and cash equivalents of $50.5 million, which, while substantial, may limit operational flexibility due to ongoing revenue shortfalls.
- Market Commitment: The company secured a $1.48 million purchase commitment for Symvess in Saudi Arabia, which not only provides short-term revenue but also potentially strengthens its market presence in the Middle East.
- Long-Term Threats: Despite recent positive developments, Humacyte faces long-term threats, particularly regarding market competition and product acceptance, which could impact its future growth potential.
See More
Humacyte Reports Q4 2025 Financial Results and Business Update
- Revenue Overview: Humacyte reported total revenues of $0.5 million for Q4 2025, with $0.4 million derived from the sale of 25 Symvess units in the U.S., indicating a growth trajectory despite ongoing challenges.
- International Market Commitment: The company secured a minimum purchase commitment of $1.475 million in Saudi Arabia for clinical evaluation and outreach programs, highlighting increasing international interest in its products.
- Defense Department Funding: The U.S. Department of Defense has authorized funding for the procurement of bioengineered blood vessels, reflecting recognition of Humacyte's technology and potentially enhancing medical solutions for American service members.
- Clinical Trial Progress: Humacyte is set to announce top-line interim results from its V012 Phase 3 study in hemodialysis access in Q2 2026, a milestone that will support its future Biologics License Application and strengthen its market position in dialysis.
See More
Humacyte Reports Q4 Net Income of -$24.804 Million, Exceeding IBES Estimate of -$23.3 Million
Financial Performance: Humacyte reported a net income of USD 24.804 million, showing a significant increase compared to the previous estimate of USD 23.3 million.
Comparison with Estimates: The current net income exceeds earlier projections, indicating a positive trend in the company's financial health.
See More
Halper Sadeh LLC Investigates Humacyte Executives' Fiduciary Duties
- Shareholder Rights Protection: Halper Sadeh LLC encourages Humacyte shareholders to contact the firm to discuss their rights and options, emphasizing the importance of timely action to protect shareholder interests and seek legal remedies.
- Corporate Governance Reform: The investigation aims to determine whether Humacyte executives breached their fiduciary duties to shareholders, and if so, shareholders may seek governance reforms and fund recovery, thereby enhancing the company's transparency and accountability.
- Legal Fee Arrangement: The firm commits to handling cases on a contingent fee basis, meaning shareholders will not incur out-of-pocket legal expenses, which reduces the financial burden of participating in legal action and encourages more shareholders to engage.
- Investor Rights Advocacy: Halper Sadeh LLC represents investors globally, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, showcasing its expertise in protecting investor rights.
See More
HUMACYTE INC.: BARCLAYS LOWERS TARGET PRICE FROM $3.5 TO $1.5
- Barclays Target Price Cut: Barclays has reduced its target price for Humacyte from $3.50 to $1.50.
- Market Impact: This significant cut reflects a shift in market expectations regarding Humacyte's performance and potential.
See More
Humacyte Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: In Q4 2025, Humacyte reported revenues of $0.5 million, with $0.4 million from U.S. sales of Symvess and $0.1 million from research collaborations, although the net loss widened to $24.8 million, indicating potential for sales growth despite challenges.
- Improved Net Loss: The full-year net loss for 2025 narrowed significantly to $40.8 million from $148.7 million in 2024, primarily due to non-cash gains related to liability remeasurements, reflecting an improvement in the company's financial health.
- Product Commercialization Progress: By the end of 2025, 27 hospitals had ordered Symvess, which was FDA-approved in December 2024, with multiple re-orders indicating growing market demand, while a $1.475 million commitment from Saudi Arabia for clinical evaluation further supports international expansion.
- R&D Pipeline Developments: Interim Phase 3 results for ATEV are expected in Q2 2026, and positive data could support a BLA filing in the second half of the year, while an IND for CTEV has been submitted, with a first-in-human Phase 1 trial planned for H2 2026, showcasing the company's ongoing innovation in bioengineered vessels.
See More
Humacyte Q4 Earnings Report Analysis
- Earnings Performance: Humacyte reported a Q4 GAAP EPS of -$0.13, aligning with expectations, but its revenue of $0.47 million fell short by $0.88 million, indicating challenges in revenue growth.
- Cash Position: As of December 31, 2025, Humacyte had cash and cash equivalents of $50.5 million, which, while substantial, may limit operational flexibility due to ongoing revenue shortfalls.
- Market Commitment: The company secured a $1.48 million purchase commitment for Symvess in Saudi Arabia, which not only provides short-term revenue but also potentially strengthens its market presence in the Middle East.
- Long-Term Threats: Despite recent positive developments, Humacyte faces long-term threats, particularly regarding market competition and product acceptance, which could impact its future growth potential.
See More
Humacyte Reports Q4 2025 Financial Results and Business Update
- Revenue Overview: Humacyte reported total revenues of $0.5 million for Q4 2025, with $0.4 million derived from the sale of 25 Symvess units in the U.S., indicating a growth trajectory despite ongoing challenges.
- International Market Commitment: The company secured a minimum purchase commitment of $1.475 million in Saudi Arabia for clinical evaluation and outreach programs, highlighting increasing international interest in its products.
- Defense Department Funding: The U.S. Department of Defense has authorized funding for the procurement of bioengineered blood vessels, reflecting recognition of Humacyte's technology and potentially enhancing medical solutions for American service members.
- Clinical Trial Progress: Humacyte is set to announce top-line interim results from its V012 Phase 3 study in hemodialysis access in Q2 2026, a milestone that will support its future Biologics License Application and strengthen its market position in dialysis.
See More
Humacyte Reports Q4 Net Income of -$24.804 Million, Exceeding IBES Estimate of -$23.3 Million
Financial Performance: Humacyte reported a net income of USD 24.804 million, showing a significant increase compared to the previous estimate of USD 23.3 million.
Comparison with Estimates: The current net income exceeds earlier projections, indicating a positive trend in the company's financial health.
See More
